The U.S. Food and Drug Administration has approved zilganersen injection, marketed as Zanvastro, marking the first treatment cleared for Alexander disease in pediatric and adult patients. The drug targets the underlying cause of the rare neurological disorder by addressing protein buildup in the brain.
Targeting the Protein Buildup
Alexander disease is a progressive condition caused by mutations in the gene responsible for producing glial fibrillary acidic protein. When this protein becomes abnormal, it accumulates in the brain’s supportive cells and damages the nervous system over time. The FDA estimates the disease affects fewer than one in a million people and presents symptoms that include seizures, loss of developmental milestones, difficulty walking, muscle weakness, and increased pressure in the brain.
Zilganersen functions as an antisense oligonucleotide designed to reduce the production of the abnormal protein before it can accumulate. The treatment is administered as an injection into the spinal canal every three months by a trained health care professional. Because of the intrathecal route and the quarterly dosing schedule, the therapy requires preparation and handling in specialty and health-system settings where the pharmacy team manages the logistics.
Related: Measles kills in Pennsylvania for first time since 1989
For patients and families, the availability of this drug represents a significant shift in management strategies. Until now, care for Alexander disease relied almost exclusively on supportive measures to manage symptoms. The introduction of a disease-modifying therapy changes the clinical approach from purely symptomatic relief to active intervention aimed at slowing the progression of motor decline.
Efficacy in the Key Study
Efficacy and safety were evaluated in a multicenter, randomized, controlled phase 3 trial. The study enrolled 49 pediatric and adult patients aged 2 years and older, plus an open-label substudy of 4 patients younger than 2 years. In patients aged 5 years and older who had measurable difficulty walking at baseline, those treated with zilganersen showed significantly better walking speed at 61 weeks compared with untreated patients. In children aged 2 to 4 years, a broader motor-skills assessment was used, with treated children improving while the control group declined.
Data presented by Ionis Pharmaceuticals at the 2026 American Academy of Neurology annual meeting quantified the primary result. The 50-mg dose produced a statistically significant stabilization of gait speed on the 10-Meter Walk Test at Week 61, with a least square mean difference of approximately 33.3% versus control (P = .041). In children aged 2 to 4 years, the Gross Motor Function Measure-88 favored treatment (least square mean difference 22.9 points; nominal P = .034).
Related: Hidden COVID protein may worsen severe cases
For the youngest patients, direct trial data were limited by the rarity of the disease and the lack of a concurrent control group. Pharmacokinetic modeling confirmed drug levels comparable to those in older children at the same dose, supported by safety data from 4 patients aged under 2 years and from older pediatric patients. This data allowed the FDA to extend the indication from infancy through adulthood.
Safety Profile and Handling
The most common adverse events reported include vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Aseptic meningitis has also been reported, requiring patients and caregivers to be counseled to report symptoms consistent with meningitis to their provider. In the key study, serious treatment-emergent adverse events occurred less frequently with zilganersen than with the control group.
The 25-mg or 50-mg groups experienced serious treatment-emergent AEs in 37.5% of cases, compared to 47.1% in the pooled control group. Zilganersen received several regulatory designations, including orphan drug, fast track, breakthrough therapy, and rare pediatric disease and priority review voucher status. The injection is now available for use in medical facilities equipped to handle the specialized administration requirements.
